Unbiased AI-powered news
2 stories related to this topic, newest first.
foxnews.comUptake of the recently approved intravenous Alzheimer’s medications has been far lower than anticipated, prompting Medicare to forecast no significant spending on Leqembi and Kisunla in 2026 or 2027. Two years ago the program projected billions of dollars annually on Leqembi alon…
Substrate placeholder — needs reviewThe U.S. Food and Drug Administration withdrew approval for a GlaxoSmithKline drug previously promoted by the Trump administration for autism treatment. In India, generic versions of GLP-1 drugs are entering the obesity treatment market. A shortage of estrogen patches used for me…